When treating certain conditions, clinicians sometimes discontinue or dial back the strength of renin-angiotensin-aldosterone system inhibitors because of hyperkalemia, a potentially dangerous side effect. A team of researchers took a closer look.
Yes, say the results of this study, which found that NSAID prescribing rates are high for patients with chronic kidney disease, despite guidelines limiting their use. To make matters potentially worse, monitoring for kidney injury was low among participants receiving NSAIDs.
These investigators claim that the risks of down-titrating or discontinuing RAASi therapy in heart failure patients with moderate hyperkalemia may be overstated.
Investigators at the University of Hawaii recently reported that, among patients hospitalized with chronic kidney disease, 1.7% experienced a preventable hospitalization and 12.3% were super-utilizers of inpatient services over a 12-month follow-up period.
This retrospective chart review of end-stage renal disease patients presenting for emergency hemodialysis suggests that QRS interval widening is predictive of hyperkalemia in this patient population but cannot be used to exclude it.
Researchers have developed a nomogram to aid clinicians in predicting hyperkalemia risk among patients receiving hemodialysis.